This inventor holds 1 USPTO granted patent. Top assignee: Dupont Pharmaceuticals Company. Active years: 2001.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2001
Title: David Nelson - Innovator in Metalloprotease Inhibition
Introduction
David Nelson is a prominent inventor based in Newark, DE (US). He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that target metalloproteinases. His work is crucial in addressing inflammatory diseases through innovative chemical solutions.
Latest Patents
David Nelson holds a patent for "Macrocyclic compounds as metalloprotease inhibitors." This invention focuses on macrocyclic molecules that inhibit metalloproteinases, including aggrecanase, and the production of tumor necrosis factor (TNF). The compounds developed by Nelson are designed to inhibit metalloproteinases involved in tissue degradation and to prevent the release of TNF. Additionally, the patent encompasses pharmaceutical compositions that utilize these compounds for treating inflammatory diseases.
Career Highlights
David Nelson is associated with DuPont Pharmaceuticals Company, where he has been instrumental in advancing research and development in his field. His innovative approach and dedication to scientific inquiry have positioned him as a key figure in pharmaceutical innovation.
Collaborations
Some of his notable coworkers include Elizabeth Arner and Jingwu Duan, who have collaborated with him on various projects within the pharmaceutical domain.
Conclusion
David Nelson's work in developing metalloprotease inhibitors represents a significant advancement in the treatment of inflammatory diseases. His contributions continue to impact the pharmaceutical industry positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile